Renjith Vijayakumar Selvarani: New Nanoparticle Approach Clears Brain Plaque and Restores Memory
Renjith Vijayakumar Selvarani, Founder, Chairman, Chief Scientific and Technology Officer at OLUSIUM, shared a post on LinkedIn about a recent article by et al, published in
“Scientists reversed Alzheimer’s symptoms with nanoparticles that cleared brain plaque and restored memory!
The new treatment cleared toxic proteins in 1 hour and reversed 6 months of cognitive decline.
In a groundbreaking development, Spanish and Chinese researchers have successfully used nanoparticles to clear Alzheimer’s-related brain plaque in mice, offering a promising new strategy in treating the disease.
The study, published in Signal Transduction and Targeted Therapy, demonstrated that just three injections of specially engineered nanoparticles reduced amyloid beta buildup in the brain by up to 60% within an hour. Even more remarkably, mice that had exhibited severe cognitive impairment began behaving normally within six months — a dramatic reversal attributed to restored function of the brain’s blood-brain barrier (BBB), a crucial defense system that becomes compromised in Alzheimer’s patients.
Rather than solely targeting plaque removal, the nanoparticles act as a ‘supramolecular drug’ to revive the BBB’s natural waste-clearing mechanisms, particularly a key protein known as LRP1. This approach tackles one of Alzheimer’s earliest warning signs: vascular damage that precedes memory loss in over 90% of patients.
By repairing the barrier’s function, the treatment improves blood flow, reduces inflammation, and allows the brain to recover its self-regulating processes. Though still in the animal-testing phase, the results open a novel research frontier that may transform how scientists detect and treat neurodegenerative diseases not just by cleaning up damage, but by restoring the body’s natural defenses.”
Title: Rapid amyloid-β clearance and cognitive recovery through multivalent modulation of blood–brain barrier transport
Authors: Junyang Chen, Pan Xiang, Aroa Duro-Castaño, Huawei Cai, Bin Guo, Xiqin Liu, Yifan Yu, Su Lui, Kui Luo, Bowen Ke, Lorena Ruiz-Pérez, Qiyong Gong, Xiaohe Tian, Giuseppe Battaglia
Read the Full Article on Signal Transduction and Targeted Therapy
Stay updated on all scientific advances with Hemostasis Today.
-
Apr 14, 2026, 17:00Anna A. Avagyan: Glad to Be Part of EHA Pediatric Hematology-Oncology Course
-
Apr 14, 2026, 16:58Ney Carter Borges: NLRP3 Inhibition in Atherosclerosis – Early Clinical Signal Beyond Lipids
-
Apr 14, 2026, 16:56Saskia Middeldorp: Excited To Write a Commentary on 2026 ACC/AHA Guideline on Acute PE
-
Apr 14, 2026, 16:54Chokri Ben Lamine: Extracorporeal Photopheresis for aGVHD cGVHD Post-SCT – 50 Pearls
-
Apr 14, 2026, 16:49Ahmed Magdi Omar: Key Takeaways From the Latest 2026 Guidelines on Antiplatelet Therapy in AIS
-
Apr 14, 2026, 16:34Hussien Hishmat: Anticoagulation in Pulmonary Embolism
-
Apr 14, 2026, 16:17ASH Is In Search of the Next Team of Authors for the 2026 ASH News Daily
-
Apr 14, 2026, 16:02EU List of Critical Medicines Webinar Recording Now Available – EHC
-
Apr 14, 2026, 15:54Omar Adwan: Patterns of Anemia